• MRSA Detection : 6 Hours

  • Group B Strep Detection : ± 6 Hours

  • E. coli Detection : 4 Hours

  • Anthrax Detection : ± 1 Hour


NanoLogix® NanoLogix FlatPack packaging allows for an extended shelf-life for our Petri plates that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix Petri plates containing TSA media in FlatPacks® have maintained viability for nutrient and moisture levels for over three years in cold storage and over two years at room temperature (RT), as compared to 3-1/2 months of useable shelf life for competitive products that require refrigeration. Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures. All of the Petri plates NanoLogix produces are packaged in FlatPack packaging to ensure the longest useable shelf life, with most of the FlatPacks we produce undergoing a further electron-beam (e-beam) processing step to provide customers with the best product for their use with an extremely long shelf life.

NanoLogix®, Inc. is a biotechnology company specializing in live cell, rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

Stock Symbol: NNLX

Reuter's Report

NanoLogix featured in Reuters Television Global Business News

<more videos>

3 Minutes with the CEO

3 Minutes With Bret Barnhizer, CEO, NanoLogix Inc.

<more videos>

Daily Buzz Report

Nanologix featured in the Daily Business Buzz Television News

<more videos>

Nanologix assists an E Coli Study by the Woman's Hospital of Texas

<Click here for the study presentation>

Presentation from Jonathan Faro at the CAOG 2016

<Click here for the complete presentation>


06.27.14 11:15 Nanologix® News:
Nanologix granted an European patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the BNP has been granted as a European Patent under the European Patent Convention. The 38 member states where this patent applies are: Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Turkey, Bulgaria, Czech Republic, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Croatia, Norway, Former Yugoslav Republic of Macedonia, San Marino, Albania, and Serbia. With the EU Patent grant, NanoLogix is electing to file for national patent issuance in the majority of the covered countries with some exceptions. This BNP patent grant joins the NanoLogix portfolio of patents for the BNP granted in Japan and Russia, and when each member state patent is issued to NanoLogix will dramatically increase the number of granted patents in our portfolio.

06.04.14 05:05 Nanologix® News:
YSU business students learn by doing
NanoLogix is pleased to have been mentioned in a news update from Youngstown State University's Williamson College of Business Administration. The update focused upon the participation of seven area companies that worked with students on their Exporting Course projects for assessing international marketing potential. The assessments were performed utilizing a powerful marketing resource database available through the University and the State of Ohio. The management and staff of NanoLogix, as a member of the local business community and as a current exporter to a number of countries, view participation in educational projects such as this as part of their duty to that community. We are pleased to have been able to contribute to the education of students about to enter their business careers. more>>>

05.20.14 01:05 Nanologix® NewsWire: Nanologix Exhibits at ASM Annual Meeting in Boston and welcomes VP for Sales and Marketing Read more>>>

04.14.14 00:05 Nanologix® News: NanoLogix's new N-Assay rapid test discussed in article by Dr. Jonathan Faro in latest issue of Med Lab Observer Read more>>>

01.27.14 00:05 Nanologix® News: State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements Read more>>>

12.04.13 12:02 Nanologix® News: Announces additional product offerings with E-Beam sterilization process - NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region Read more>>>

06.21.13 NanoLogix BNP Instructional Video

06.11.13 02:31 Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>

04.30.13 06:00 Nanologix® News: NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>

04.02.13 10:29 Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..

03.13.13 10:29 Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. Read more>>>

11.09.12 Nanologix® News: NanoLogix Subject of EPA Featured News article. Read more>>

6.13.12 Health News Texas: Texas Health Science Center-Huston instrumental in New NanoLogix Technology Read the article>>



  • Aug 2,2018:
    NanoLogix Welcomes Dr. Jonathan Faro to Board of Directors.

    HUBBARD, OH--(Interweb - April 28, 2017) - NanoLogix, Inc. (OTC PINK: NNLX), Jonathan Faro, PhD, MD, joins as Director of Medical Development NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company's Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and identification technology and primary author of a number of published peer-reviewed research papers on the technology.
  • April 28, 2017:
    N-Assay To Be Presented at AACC Annual Meeting.

    HUBBARD, OH--(Interweb - April 28, 2017) - NanoLogix, Inc. (OTC PINK: NNLX), NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific
  • Dec 6, 2016:
    Nanologix is seeking larger production plant.

    HUBBARD, OH--(Marketwired - Dec 9, 2016) - NanoLogix, Inc. (OTC PINK: NNLX), The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed.
  • Nov 11, 2016:
    EU and& Hong Kong FlatPack Patent Approval Notice Received.

    HUBBARD, OH--(Marketwired - Nov 11, 2016) - NanoLogix, Inc. (OTC PINK: NNLX), NanoLogix is extremely pleased to announce receipt of notice from their London patent firm, Forresters, of patent approval in the European Union and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack.
  • Nov 11, 2016:
    A senior CAOG member stated "This is great technology, truly a disruptive tech, we need it for rapid detection and determination of antibiotic resistance, it's essential."

    HUBBARD, OH--(Marketwired - Nov 11, 2016) - NanoLogix, Inc. (OTC PINK: NNLX), According to Clayton M. Christensen, a Harvard Business School professor, a disruptive technology is a new emerging technology that unexpectedly displaces an established one. ... The Innovator's Dilemma by Clayton M. Christensen.
  • Nov 2, 2016:
    NanoLogix Rapid Bacteria Test Unveiled at CAOG, Wins Judges Choice Award; Technology Published in Journal of Infectious Diseases in Obstetrics and Gynecology

    HUBBARD, OH--(Marketwired - Nov 1, 2016) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection and identification of bacteria, is excited to announce the unveiling of the N-Assay, their new technology for unparalleled rapid, accurate, and sensitive detection and identification of targeted bacteria, including specific determination of antibiotic sensitivity.
  • Oct 30, 2016:
    NanoLogix N-Assay technology published in Infectious Diseases in Obstetrics and Gynecology publication

    HUBBARD, OH--(Marketwired - Oct 30, 2016) - NanoLogix, Inc. ( OTC PINK : NNLX ), NanoLogix is pleased to announce that at the CAOG Annual Meeting in Las Vegas, Jonathan Faro MD PhD received the "Judges' Choice Gynecology Poster Presentation Award" for the N-Assay research presentation. The award is both a certificate and financial.
  • Oct 6, 2016:
    NanoLogix N-Assay Technology To Be Presented at CAOG Annual Meeting in Las Vegas

    HUBBARD, OH--(Marketwired - Oct 6, 2016) - NanoLogix, Inc. ( OTC PINK : NNLX ), NanoLogix is pleased to announce that their N-Assay diagnostic technology will be presented by Dr. Jonathan Faro (MD, PhD) at the Central Association of Obstetricians & Gynecologists (CAOG) annual meeting, to be held at the Venetian Resort and Casino in Las Vegas, NV Oct. 26-29, 2016.